Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 mg QD in Patients Chronically Infected With Hepatitis B Virus

NCT00313287 is registered in ClinicalTrials.gov with Bukwang Pharmaceutical as lead sponsor.

NCT NCT00313287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00313287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 mg QD in Patients Chronically Infected With Hepatitis B Virus
Lead sponsor
Bukwang Pharmaceutical
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2003
Completion date
November 30, 2004
Enrollment
180
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b